Faisal Ghiath Sukhtian has bought OTLK on 3 days since Dec 2021
Director at Outlook Therapeutics, Inc.
SEC CIK 0001716033 · Filings on SEC.gov ↗
Faisal Ghiath Sukhtian's record
3 months after each buy, from the first price a copier could get.
2 buys have 3 months of prices so far. A record shows here at 3.
Every filing
3 filings since Dec 2021, newest first
About Faisal Ghiath Sukhtian
Faisal Ghiath Sukhtian is a director and, since 2025, Chairman of the Board of Outlook Therapeutics, Inc. (NASDAQ: OTLK), where he has served on the board since 2017.( As a significant insider at the company, he has reported multiple equity transactions in Outlook Therapeutics stock, including open-market purchases and stock option grants, and is listed as both a director and a 10% owner in insider rosters.( His Form 4 filings show activity such as a 30,000‑share purchase in October 2022 and option grants totaling 404,030 shares in 2025.(
Professionally, Sukhtian is Executive Director at GMS Holdings, where he oversees a number of healthcare and life sciences investments and serves as a director on the firm’s board.( He has extensive experience in operations, strategy development, and mergers and acquisitions in the biopharma and life sciences sectors, and holds multiple board roles, including Chairman of the Board of Genepharm, and board member of MS Pharma and Agri Sciences.( Publicly available filings and company disclosures emphasize his investment management and board leadership background; specific educational details are not disclosed in the cited sources.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.